Loading...
XHKG1312
Market cap19mUSD
Dec 27, Last price  
0.03HKD
1D
0.00%
1Q
-18.18%
Jan 2017
-96.03%
IPO
-87.50%
Name

Kontafarma China Holdings Ltd

Chart & Performance

D1W1MN
XHKG:1312 chart
P/E
—
P/S
0.19
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.45%
Rev. gr., 5y
-17.32%
Revenues
809m
-9.50%
451,444,000725,298,000704,698,000703,468,000733,125,000465,739,000633,279,0001,344,336,0002,093,724,0001,482,347,0001,009,134,000961,089,000894,062,000809,107,000
Net income
-29m
L-73.72%
168,332,00076,158,00026,834,00032,564,00017,280,000-34,237,000-37,076,000-1,806,00032,499,00065,211,000-20,085,000-4,553,000-109,744,000-28,843,000
CFO
37m
P
115,805,000-7,609,00045,311,000-64,462,000-8,130,000-14,735,00012,432,000-47,262,00066,864,00025,670,000206,933,00075,068,000-2,165,00037,119,000
Dividend
May 27, 20130.02 HKD/sh
Earnings
Mar 26, 2025

Profile

Tongfang Kontafarma Holdings Limited, an investment holding company, engages in the manufacture and sale of prescription drugs and laboratory related products in Mainland China, Singapore, Taiwan, and the United States. The company operates in Pharmaceutical Business and Fitness Business segments. It also offers chemical drugs and prescribed traditional Chinese medicines; operates fitness centers; operates in the franchise business; and provides consultation services for fitness and health activities. The company trades in laboratory related products; researches and develops medical products; and offers corporate advisory services. As of December 31, 2021, it operated 12 fitness centers and 2 yoga center in Taiwan; and 10 fitness centers in Singapore. The company was formerly known as Allied Cement Holdings Limited and changed its name to Tongfang Kontafarma Holdings Limited in August 2016. The company was founded in 1993 and is headquartered in Wan Chai, Hong Kong. Tongfang Kontafarma Holdings Limited is a subsidiary of China Health Management Investment Limited.
URL
https://www.tfkf.com.hk/
IPO date
Jan 18, 2012
Employees
715
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
809,107
-9.50%
894,062
-6.97%
961,089
-4.76%
Cost of revenue
901,057
975,637
1,013,059
Unusual Expense (Income)
NOPBT
(91,950)
(81,575)
(51,970)
NOPBT Margin
Operating Taxes
17,196
(7,992)
4,227
Tax Rate
NOPAT
(109,146)
(73,583)
(56,197)
Net income
(28,843)
-73.72%
(109,744)
2,310.37%
(4,553)
-77.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
105,680
222,580
306,584
Long-term debt
509,619
696,939
907,516
Deferred revenue
982
22,834
14,550
Other long-term liabilities
12,230
13,336
14,252
Net debt
527,640
734,121
1,024,526
Cash flow
Cash from operating activities
37,119
(2,165)
75,068
CAPEX
(23,923)
(51,679)
(124,383)
Cash from investing activities
144,143
121,531
23,243
Cash from financing activities
(198,812)
(137,332)
(99,802)
FCF
(38,713)
143,045
(58,802)
Balance
Cash
87,659
142,595
183,962
Long term investments
42,803
5,612
Excess cash
47,204
140,695
141,520
Stockholders' equity
39,980
119,340
251,478
Invested Capital
1,369,001
1,614,137
1,917,604
ROIC
ROCE
EV
Common stock shares outstanding
5,578,714
5,578,714
5,578,714
Price
0.04
-20.00%
0.05
-8.16%
0.05
-37.97%
Market cap
200,834
-20.00%
251,042
-8.16%
273,357
-37.97%
EV
733,131
1,522,491
1,876,438
EBITDA
15,214
49,170
93,163
EV/EBITDA
48.19
30.96
20.14
Interest
15,250
23,278
34,175
Interest/NOPBT